Skip to main content
Premium Trial:

Request an Annual Quote

Gen InCode: Bill Rhodes

Gen InCode, a privately owned UK-based company specializing in cardiovascular disease genetic risk assessment, has appointed Bill Rhodes as non-executive chairman. Rhodes has previously served as worldwide president of Becton Dickinson's Biosciences business and was BD's corporate executive officer for strategy and corporate development. Rhodes also currently serves as chairman at OpGen, Omega Diagnostics Group, and CytoSmart Technologies. He was formerly chairman of the Curetis supervisory board until that company's merger with OpGen.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.